Published in Psychiatry Res on March 22, 1999
So depression is an inflammatory disease, but where does the inflammation come from? BMC Med (2013) 2.02
Depressive symptoms, omega-6:omega-3 fatty acids, and inflammation in older adults. Psychosom Med (2007) 1.54
Long chain omega-3 fatty acids intake, fish consumption and mental disorders in the SUN cohort study. Eur J Nutr (2007) 1.45
The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry (2012) 1.41
Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J Affect Disord (2010) 1.23
Higher dietary intake of long-chain omega-3 polyunsaturated fatty acids is inversely associated with depressive symptoms in women. Nutrition (2009) 1.11
New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology (2012) 1.06
Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol (2012) 1.05
Omega-3 fatty acids and major depression: a primer for the mental health professional. Lipids Health Dis (2004) 1.03
Considerations regarding neuropsychiatric nutritional requirements for intakes of omega-3 highly unsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids (2009) 1.00
Depressed mood and n-3 polyunsaturated fatty acid intake from fish: non-linear or confounded association? Soc Psychiatry Psychiatr Epidemiol (2006) 0.99
Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: Interactions with reproductive status in female rats. Psychoneuroendocrinology (2008) 0.96
Oiling the brain: a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan. Nutrients (2010) 0.96
Fatty acid composition in postmortem brains of people who completed suicide. J Psychiatry Neurosci (2007) 0.95
Omega-3 fatty acid deficiency during perinatal development increases serotonin turnover in the prefrontal cortex and decreases midbrain tryptophan hydroxylase-2 expression in adult female rats: dissociation from estrogenic effects. J Psychiatr Res (2008) 0.95
Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br J Cancer (2004) 0.95
Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease. Brain Res (2014) 0.94
Omega-3 fatty acid deficiency increases constitutive pro-inflammatory cytokine production in rats: relationship with central serotonin turnover. Prostaglandins Leukot Essent Fatty Acids (2010) 0.93
Role of docosahexaenoic acid in maternal and child mental health. Am J Clin Nutr (2009) 0.90
Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: a randomized controlled trial. PLoS One (2012) 0.90
Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxid Med Cell Longev (2014) 0.89
Fish consumption and omega-3 polyunsaturated fatty acids in relation to depressive episodes: a cross-sectional analysis. PLoS One (2010) 0.89
Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord (2010) 0.88
Membrane omega-3 Fatty Acid deficiency as a preventable risk factor for comorbid coronary heart disease in major depressive disorder. Cardiovasc Psychiatry Neurol (2009) 0.87
Omega-3 Supplementation for Psychotic Mania and Comorbid Anxiety in Children. J Child Adolesc Psychopharmacol (2015) 0.86
Dopamine receptor alterations in female rats with diet-induced decreased brain docosahexaenoic acid (DHA): interactions with reproductive status. Nutr Neurosci (2010) 0.86
Omega-3 polyunsaturated fatty acid (PUFA) status in major depressive disorder with comorbid anxiety disorders. J Clin Psychiatry (2013) 0.86
Nutritional interventions in depression and perinatal depression. Yale J Biol Med (2013) 0.85
Do pregnant women and those at risk of developing post-natal depression consume lower amounts of long chain omega-3 polyunsaturated fatty acids? Nutrients (2010) 0.85
Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. Eur Arch Psychiatry Clin Neurosci (2004) 0.84
The omega-3 fatty acid eicosapentaenoic acid is required for normal alcohol response behaviors in C. elegans. PLoS One (2014) 0.83
Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder. Int J Neuropsychopharmacol (2013) 0.82
Cholesterol and affective morbidity. Psychiatry Res (2009) 0.81
Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression? Curr Neuropharmacol (2012) 0.81
A Meta-Analysis of Oxidative Stress Markers in Depression. PLoS One (2015) 0.80
Emerging risk factors for postpartum depression: serotonin transporter genotype and omega-3 fatty acid status. Can J Psychiatry (2012) 0.80
Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial. Clin Psychopharmacol Neurosci (2014) 0.80
Nutrition and late-life depression: etiological considerations. Aging health (2010) 0.79
Association between Fish Consumption and Prefrontal Function during a Cognitive Task in Male Japanese Workers: A Multi-Channel Near-Infrared Spectroscopy Study. PLoS One (2015) 0.79
(N-3) Fatty acids: molecular role and clinical uses in psychiatric disorders. Adv Nutr (2012) 0.79
Reduced cholesterol is associated with the depressive-like behavior in rats through modulation of the brain 5-HT1A receptor. Lipids Health Dis (2015) 0.78
The role of vitamins and minerals in psychiatry. Integr Med Insights (2008) 0.78
The Role of Nutrients in Protecting Mitochondrial Function and Neurotransmitter Signaling: Implications for the Treatment of Depression, PTSD, and Suicidal Behaviors. Crit Rev Food Sci Nutr (2016) 0.78
Omega-3 fatty acids and multiple sclerosis: relationship to depression. J Behav Med (2008) 0.78
Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram. Ann Clin Psychiatry (2010) 0.78
Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer. Br J Cancer (2005) 0.77
Fibroblasts from patients with major depressive disorder show distinct transcriptional response to metabolic stressors. Transl Psychiatry (2015) 0.76
Serum polyunsaturated fatty acids are not associated with the risk of severe depression in middle-aged Finnish men: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) study. Eur J Nutr (2010) 0.75
Do sex hormones or hormone therapy modify the relation of n-3 fatty acids with incident depressive symptoms in postmenopausal women? The MESA Study. Psychoneuroendocrinology (2016) 0.75
Lipid correlates of attentional impulsivity in first episode mania: results from an Indian population. Indian J Psychol Med (2014) 0.75
N-3 (omega-3) Fatty acids in postpartum depression: implications for prevention and treatment. Depress Res Treat (2010) 0.75
The Role of Lipid Biomarkers in Major Depression. Healthcare (Basel) (2017) 0.75
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry (1999) 5.63
Erythropoietin response is blunted in critically ill patients. Intensive Care Med (1997) 3.20
The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine (1998) 2.70
Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine (1997) 2.43
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther (1994) 2.27
Outcome in manic disorders. A naturalistic follow-up study. Arch Gen Psychiatry (1990) 2.15
A novel augmentation strategy for treating resistant major depression. Am J Psychiatry (2001) 2.05
Neuroleptic-induced prolactin level elevation and breast cancer: an emerging clinical issue. Arch Gen Psychiatry (1978) 2.02
Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol (2003) 1.89
Clozapine: is another view valid? Am J Psychiatry (1995) 1.84
Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry (2000) 1.68
Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord (1995) 1.65
The dopamine hypothesis of schizophrenia: a review. Schizophr Bull (1976) 1.65
Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry (1994) 1.64
RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology (2001) 1.62
Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci (1997) 1.60
Effects of needle size and storage temperature on measurements of serum potassium. Clin Chem (1986) 1.56
Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Arch Gen Psychiatry (1995) 1.55
Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry (1989) 1.48
Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry (1991) 1.48
5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem (2001) 1.43
The role of cognition in vocational functioning in schizophrenia. Schizophr Res (2000) 1.43
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) (2004) 1.42
A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol (2002) 1.41
Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord (1996) 1.40
Regional differences of HFE (C282Y, H63D) allele frequencies in the Netherlands A model case illustrating the significance of genographics and prehistorical population migration. Acta Clin Belg (2013) 1.39
Estimation of brain lesion size based on quantifying CK-BB release. Clin Chem (1990) 1.39
Effect of clozapine on psychogenic polydipsia in chronic schizophrenia. J Clin Psychopharmacol (1991) 1.39
Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry (1993) 1.33
The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull (1989) 1.31
Does cerebrovascular disease affect the coupling between neuronal activity and local haemodynamics? Brain (2003) 1.31
Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry (1993) 1.29
Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther (1997) 1.29
The relationship between smooth pursuit performance, motion perception and sustained visual attention in patients with schizophrenia and normal controls. Psychol Med (1997) 1.28
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem (1996) 1.26
The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry (1976) 1.25
Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res (1995) 1.25
Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry (2001) 1.25
Eye-tracking dysfunctions in schizophrenic patients and their relatives. Arch Gen Psychiatry (1974) 1.24
Risk and preventive factors of post-traumatic stress disorder (PTSD): alcohol consumption and intoxication prior to a traumatic event diminishes the relative risk to develop PTSD in response to that trauma. J Affect Disord (2001) 1.22
Increased cerebral vasomotor reactivity in migraine with aura: an autoregulation disorder? A transcranial Doppler and near-infrared spectroscopy study. Cephalalgia (2008) 1.22
The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res (1998) 1.19
Proteinuria as complication of simvastatin treatment. Lancet (1990) 1.19
Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta (2004) 1.18
Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res (1995) 1.18
The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Mol Psychiatry (2013) 1.16
In humans, serum polyunsaturated fatty acid levels predict the response of proinflammatory cytokines to psychologic stress. Biol Psychiatry (2000) 1.16
Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal immunoglobulins: 2 case reports and a review of the literature. Acta Clin Belg (2005) 1.16
Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther (1988) 1.15
Perceptual adjustment to time-compressed speech: a cross-linguistic study. Mem Cognit (1998) 1.14
Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res (2001) 1.14
Non-esterified fatty acids in follicular fluid of dairy cows and their effect on developmental capacity of bovine oocytes in vitro. Reproduction (2005) 1.14
Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr Scand (1997) 1.14
Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res (1997) 1.13
Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther (1992) 1.13
Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology (1986) 1.12
Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord (2000) 1.12
The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther (2011) 1.10
Effect of clozapine on human serum prolactin levels. Am J Psychiatry (1979) 1.09
Seasonality in violent suicide but not in nonviolent suicide or homicide. Am J Psychiatry (1993) 1.09
Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry (1994) 1.08
Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res (1994) 1.08
Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation (2001) 1.08
Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging (2003) 1.07
Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol Psychiatry (1999) 1.07
Association between leisure time physical activity and markers of chronic inflammation related to coronary heart disease. Atherosclerosis (2004) 1.07
The effect of buspirone on prolactin and growth hormone secretion in man. Arch Gen Psychiatry (1983) 1.07
Factors affecting serum creatine phosphokinase levels in the general population: the role of race, activity and age. Clin Chim Acta (1971) 1.06
A combined thin layer-gas chromatographic method for the analysis of fatty acid-containing stool fractions. Clin Chim Acta (1972) 1.06
The correlates and alleged biochemical background of the resazurin reduction test in semen. Int J Androl (1998) 1.05
Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol (1995) 1.05
Determination of carbohydrate-deficient transferrin using capillary zone electrophoresis. Clin Chem (2001) 1.05
Neuroimaging experimental studies on brain plasticity in recovery from stroke. Eura Medicophys (2007) 1.04
Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry (2001) 1.04
Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry (1999) 1.04
Are the common assimilate pool and trophic relationships appropriate for dealing with the observed plasticity of grapevine development? Ann Bot (2009) 1.04
Clozapine for treatment-refractory mania. Am J Psychiatry (1996) 1.03
Rigidity, hyperpyrexia and coma following fluphenazine enanthate. Psychopharmacologia (1973) 1.03
Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry (1997) 1.03
Comparison of three approaches to model grapevine organogenesis in conditions of fluctuating temperature, solar radiation and soil water content. Ann Bot (2010) 1.03
Muscle abnormalities in acute psychoses. Arch Gen Psychiatry (1970) 1.02
Psychiatric morbidity and comorbidity following accidental man-made traumatic events: incidence and risk factors. Eur Arch Psychiatry Clin Neurosci (2000) 1.02
Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res (1993) 1.02
Effect of buspirone on prolactin secretion is not mediated by 5-HT-1a receptor stimulation. Arch Gen Psychiatry (1992) 1.01
Physiologic abnormalities of the neuromuscular system in schizophrenia. Schizophr Bull (1977) 1.01
Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology (1997) 1.01
Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther (1999) 1.01
Prognostic value of gastric intramural pH in surgical intensive care patients. Crit Care Med (1988) 1.00
Human platelet alpha 2-adrenergic receptors: labeling with 3H-yohimbine, a selective antagonist ligand. Life Sci (1981) 0.99
Mutations and phenotype in isolated glycerol kinase deficiency. Am J Hum Genet (1996) 0.99
Lower serum zinc in major depression in relation to changes in serum acute phase proteins. J Affect Disord (1999) 0.99
Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology (1998) 0.99
Normal reference values for creatine, creatinine, and carnitine are lower in vegetarians. Clin Chem (1989) 0.99
Associations between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. Atherosclerosis (1999) 0.99